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Section 1. Introduction
Document aims
Synthetic opioids, including fentanyl, are important therapeutic medicines that 
are used widely for pain, as well as for anaesthesia, in combination with other 
medication. This document focuses on the misuse of fentanyl, fentanyl analogues* 
and other novel synthetic opioids and does not address issues pertaining to their use 
in legitimate therapeutic and clinical contexts. Specifically, this document focuses on 
the clinical management of the health-related harms associated with the misuse of 
these substances, both acute harms as well as harms from frequent and long-term 
use (chronic harms). It is aimed primarily at a clinical audience.
Although there is a large body of evidence on pharmaceutical synthetic opioids and 
fentanyl and its analogues, the evidence on the novel fentanyls and other novel 
opioids, their harms and management, is currently limited and cannot be considered as 
robust. Nonetheless, the research findings are broadly consistent and this document 
provides clinically relevant information based on the best evidence currently available. 
Misuse of synthetic opioids
Although fentanyl, fentanyl analogues and other synthetic opioids play an important 
and well documented therapeutic role, their misuse, especially in high doses, can lead 
to acute toxicity and life-threatening adverse effects.1 Fentanyl and other synthetic 
opioids also have a high liability to misuse and chronic adverse effects, including 
dependence. 
The misuse of fentanyl and other synthetic opioids is not a recent phenomenon. In 
the 1970s and 1980s, products containing fentanyl and its analogues appeared on the 
illicit drug market, and were associated with accidental overdoses.2,3 Today, in some 
parts of the world novel synthetic opioids are once again associated with an overdose 
epidemic.4 It has been noted by Rudd et al. that as the numbers of deaths from natural 
and semi-synthetic opiates were stabilising in the US over the period 2010–15, deaths 
from synthetic opioids and illicitly manufactured fentanyls were rising at an alarming 
rate.5
Geographical patterns of use
There are geographical differences in the aetiology and extent of the crisis. In North 
America, the significant increase in the misuse of synthetic opioids and overdose-related 
* For the sake of convenience, this document will sometimes use the generic term of ‘fentanyls’ to refer 
to fentanyl and its analogues.
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deaths was initially associated with addiction to legitimately prescribed opioid pain 
medicines. At the moment, dependence on prescription opioids does not appear to 
have played a significant role in its illicit/non-medical use in Europe (including the UK), 
as it has in North America,6 although the possibility of under-reporting cannot be 
dismissed.7
What Europe, including the UK, shares with the US and Canada is the recent emergence 
of novel highly potent synthetic opioids, in particular fentanyl derivatives and other 
substances, that are linked with significant risk of acute toxicity and overdose. Although 
the number of novel synthetic opioid analogues detected is small in comparison with 
other types of novel psychoactive substance (NPS), such as stimulants, the largest 
percentage increase in recent years has been observed in the synthetic opioids.
At a global level, synthetic opioids represented 4 per cent of all NPS at the end of 
December 2016, as shown in Figure 1, as opposed to only 2 per cent at the end of 
2014.8 Between 2012 and 2016, 17 novel fentanyl analogues were reported to the 
United Nations Office on Drugs and Crime (UNODC) Early Warning Advisory from 
countries in East Asia, Europe and North America.* 3 These are usually manufactured 
in clandestine laboratories and are referred to as non-pharmaceutical fentanyls (NPFs). 
Similarly, 25 novel opioids have been detected on Europe’s drug market since 2009, 
including 9 reported for the first time in 2016. These include 18 fentanyls, 8 of which 
* New fentanyls reported: 3-fluorofentanyl; 4-fluorobutyrfentanyl; 4-methoxybutyrfentanyl; acetyl-
fentanyl; acrylfentanyl; beta-hydroxy-thiofentanyl; butyrfentanyl; despropionylfentanyl; des propionyl-
2-fluorofentanyl; furanylfentanyl; isobutyrfentanyl; (iso)butyr-F-fentanyl N-benzyl analogue; methoxy-
acetylfentanyl; ocfentanil; para-fluoroisobutyrfentanyl; tetrahydrofuranyl fentanyl; valeryl fentany.
Figure 1. Proportion of NPS by pharmacological effect (December 2016) 
Source: United Nations Office on Drugs and Crime (UNODC), World Drug Report 2017
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were reported for the first time in 2016.7 The increase in opioid NPS detected in recent 
years is shown in Figure 2.
For individuals and criminal organisations involved in the illicit drug trade, fentanyl 
offers a number of ‘advantages’ over the established opioid, heroin. Fentanyls have 
greater potency, resulting in less bulk and weight to transport and distribute than is 
the case with heroin. Fentanyls can be manufactured reliably and in large quantities 
from abundant chemical precursors, whereas heroin requires an opium crop, which 
must be produced in the open air.3 The low production cost and wholesale cost of 
fentanyl in comparison with heroin has been identified as a reason for the recent 
increase in fentanyl on illicit markets. In 2017, for example, the reported wholesale cost 
of heroin was approximately $65,000 per kilogram, whereas fentanyl was available at 
roughly $3,500 per kilogram.9 
The numbers of heroin- and fentanyl-related overdoses are rising worldwide,10 with 
very large numbers of deaths reported in the US and Canada, as discussed below. 
Although this situation is not reflected in Europe, some fatalities associated with 
these substances have been reported in mainland Europe and in the UK but, at 
present, synthetic opioids, including fentanyls, used for non-medical purposes in the 
UK can be described as ‘low use but high risk/harm’ substances. Vigilance is required, 
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Figure 2. Number and categories of new psychoactive substances notified to the EU Early 
Warning System for the first time, 2005–16 
Source: EMCDDA- European Drug Report 2017
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as well as improved confidence and competence in the identification, assessment and 
management of their harms in clinical practice.
Legal status in the UK
In the UK, fentanyl is classified as a controlled Class A drug under the Misuse of Drugs 
Act 1971. Almost all novel fentanyls are covered by the UK’s generic control (Class A) 
but UK control of precursors is (currently) governed by EU regulations, as it is classed 
as a trade issue. The fentanyl precursors NPP and ANPP were due to be controlled in 
the UK under the EU regulations in 2018.
The synthetic opioids AH-7921, MT-45 and U-47700 are Class A drugs under the 
Misuse of Drugs Act 1971. All other psychoactive substances not currently covered by 
that Act now fall under the Psychoactive Substances Act 2016.
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Section 2. Fentanyl and fentanyl 
derivatives and analogues
Pharmacology 
Fentanyl (N-[1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide) is a potent opioid 
used in human and veterinary medicine. It has analgesic and sedative effects and is 
widely used in the management of severe pain and in anaesthesia.3 Fentanyl is a full 
agonist at the μ-opioid receptor. It is at least 80 times more potent than morphine11,12 
and when misused is associated with a risk of acute toxicity. Carfentanyl is intended 
only for veterinary use on large animals, and is not approved for medical use in humans; 
it is estimated to be about 10,000 times more potent than morphine.3,13,14 
Fentanyl derivatives sold on the illicit market include analogues that have been 
rediscovered by the manufacturers from studies described in the scientific literature 
but never developed into pharmaceutical products.* There are also newly designed 
fentanyl analogues made by new modifications of the fentanyl chemical structure, 
to avoid legal control, as with other NPS. They are sometimes referred to as non-
pharmaceutical fentanyls (NPF) and include:
•	furanylfentanyl, or N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide; 
•	acryloylfentanyl, or N-(1phenethylpiperidin-4-yl)-N-phenylacrylamide;
•	acrylofentanyl, or N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; 
•	para-fluoroisobutyrfentanyl;
•	4-fluorobutyrfentanyl. 
Fentanyl has a rapid onset of action, almost immediate following intravenous admin-
istration, but its maximal analgesic and respiratory depressant effect may not be 
noted for several minutes. Following intramuscular administration, the onset of action 
is from 7–8 minutes and the duration of action is 1–2 hours. The duration of action of 
fentanyl, when administered intravenously, is 30–60 minutes,15,16 much shorter than 
with heroin (4–5 hours). This may lead to frequent redosing.17 
Overall, reasons for the potency of fentanyl include its high lipophilicity (which allows it 
easily to cross the blood–brain barrier) and high receptor affinity, with high selectivity 
and specificity for the μ-opioid receptor over other opioid receptor subtypes.18 In 
terms of toxicity, as potent agonists of the µ-opioid receptor, fentanyls are associated 
with a number of acute physiological effects, including respiratory depression. 
* Examples include acetylfentanyl, butyrfentanyl, furanylfentanyl (N-phenyl-N-[1-(2-phenylethyl) 
piperidin-4-yl]furan-2-carboxamide) and ocfentanil.
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Previously developed fentanyl analogues have properties similar to fentanyl,* but 
current knowledge of novel non-pharmaceutical analogues is limited and these drugs 
may differ in their potency, efficacy and duration of action.19,20
The misuse of fentanyls is associated with a high risk of acute toxicity, or ability to 
cause harm through a single or short-term exposure to the drug. For fentanyl, the 
estimated lethal dose in humans could be as low as 2 mg by intravenous injection. 
Information on the effect of the novel non-pharmaceutical fentanyls, especially in 
humans, is currently very limited. Nonetheless, in vitro studies have established that 
furanylfentanyl is a potent agonist of the µ-opioid receptor. Cases of acute intoxication 
suspected to be due to furanylfentanyl reported in Europe showed clinical features 
generally consistent with opioid-like toxicity and included life-threatening effects; 
toxicological data on these deaths where furanylfentanyl was detected suggest that 
the drug was the cause of death or was likely to have contributed to death (even in 
presence of other substances).21,22 Similarly, although the acute toxicity of acryloyl-
fentanyl in humans has not been determined, observations from a study conducted 
in mice suggest that it is similar to that of fentanyl, with considerable risk of acute 
toxicity through respiratory depression;23 moreover, cases of acute toxicity associated 
with acryloylfentanyl have been reported in Swedish studies.24
Markets
Fentanyls destined for the illicit market appear to come from both:
•	diversion of fentanyl-containing medicines from the regulated supply chain,25 
(significant in some parts of the world but which does not appear to be significant 
in the UK at the present time), and 
•	illicit production in clandestine laboratories of non-pharmaceutical fentanyls.
* Examples of fentanyls that have not been approved for medical use, are listed below:
•	acetylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide; acetyl fentanyl, desmethyl 
fentanyl, MCV 4848, NIH 10485);
•	acryloylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] prop-2-enamide, acrylfentanyl, 
acryloyl-F, Acr-F, ACF); 
•	alpha-methylfentanyl (N-phenyl-N-[1-(1-phenyl-2-propanyl) piperidin-4-yl] propanamide);
•	3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin- 4-yl]-N-phenylpropanamide,  
mefentanyl, 3-MF);
•	butyrylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide, butyl fentanyl, BF); 
•	4-methoxybutyrylfentanyl (N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butan amide, 
4-MeO-BF); 
•	4-fluorobutyrylfentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide, 
4-FBF); 
•	4-fluoroisobutyrylfentanyl (N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl] 
propan amide, 4F-iBF);
•	4-chloroisobutyrylfentanyl (N-(4-chlororophenyl)-2-methylN-[1-(2-phenylethyl)piperidin-4-yl]
propanamide, 4F-iBF);
•	furanylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin- 4-yl]-2-furancarboxamide, furafentanyl);
•	cyclopentylfentanyl (N-(1-phenylethylpiperidin-4-yl)-Nphenylcyclopentanecarboxamide, CP-F); 
•	tetrahydrofuranylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxam-
ide, tetrahydrofuranfentanyl, THF-F);
•	ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide, 
ocfentanil, A-3217).
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Synthetic opioids used for non-medical purposes, including fentanyl and its analogues, 
are sold online, typically on the ‘darknet’*,26 as well as by dealers in the illicit market. 
Mode of use
Fentanyl and its salts are typically white granular or crystalline powders. Clandestinely 
manufactured fentanyl or its analogues are sold in solid or liquid forms,3 including 
powders, pills, capsules, patches, lozenges and liquid and on blotting paper. Although 
less common, furanylfentanyl has also been seized in Europe as a green ‘herbal’ 
material, as well as being sold as e-liquids for vaping in electronic cigarettes.21 
Fentanyl and its analogues may be consumed	by several routes, including injecting 
(intravenous or intramuscular), orally, transdermally, by smoking,27 intra-nasally or 
sublingually through a spray or vaporisation.21 Also worth noting are new forms of 
pharmaceutical fentanyl, for example for oromucosal administration as ‘lollipops’.
One concern noted in the EMCDDA European Drug Report 2017 was the appearance 
on the market of nasal sprays containing non-pharmaceutical fentanyls, such as 
acryloyl fentanyl and furanylfentanyl.7
In the UK at the current time, fentanyl, fentanyl analogues and other new synthetic 
opioids are mainly sold on the illicit market as heroin or mixed with heroin to people 
who believe they are receiving heroin. There are in addition reports from elsewhere in 
the world that they are also sold as, or mixed with, other illicit drugs and counterfeit 
medicines.7
International evidence suggests that fentanyl products have also been found in 
products sold as cocaine, or crack cocaine, ‘black tar’ heroin and MDMA.3,28 Further-
more, there are reports of individuals purchasing prescription medication, such as 
oxycodone9 and alprazolam (Xanax),29,30 on the internet only to be sold counterfeit 
products that contain new fentanyls.31,32
Diverted pharmaceutical fentanyl does not seem to be a significant problem in the UK 
at this time. In some countries, however, fentanyl has been reported to be diverted 
from pharmaceutical products, mostly extracted from transdermal patches, and to 
a lesser extent lozenges, sublingual tablets and solutions of fentanyl intended for 
infusion. 
In addition to diverted fentanyl products, even ‘exhausted’ medical transdermal 
patches will still contain significant amounts of fentanyl when removed and so need 
to be disposed of responsibly.
Fentanyl transdermal patches can be misused in a variety of ways, including:
•	extraction of gel for injection or ingestion; 
•	heating the patch in a glass container and inhaling the fentanyl emitted; 
* The darknet is an encrypted part of the internet, sometimes also referred to as cryptomarkets. They 
provide a largely anonymous platform for trading in illicit goods and services, with drugs estimated 
to account for around two-thirds of darknet market activity. 
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•	smoking on foil; 
•	using on the skin; 
•	cutting into pieces and sucking or swallowing; 
•	inhalation via a vaporiser. 
There are also reports of patches being simmered in a small volume of water and 
the solution obtained injected intravenously; and of frozen patches being cut into 
pieces and then placed under the tongue or in the cheek cavity for drug absorption, 
or inserted into the rectum.9,20,25,27,33,34,35,36,37,38,39 
Desired effects of fentanyls
The effects of fentanyls that are desired by those who use them outside medical 
supervision are similar to those of other opioids and include analgesia, anxiolysis, 
euphoria, drowsiness and feelings of relaxation, with some suggestion that the latter 
are less pronounced than with heroin and morphine.40,41
There are reports of heroin users being suspicious that they had unknowingly 
consumed a new synthetic opioid, as their experience of the drug effect was different 
from normal.42 Some research suggests that users who were unaware that they had 
used a fentanyl (initially believing that they were administering heroin) described the 
effects of fentanyls as stronger and qualitatively different from those of heroin,43 or 
describe the experience as like taking heroin but more intense.44,45,46 
Unwanted effects of fentanyls
Studies have shown that a substantial number of people who had used fentanyl 
did not know that they had done so when they consumed the drug, but thought 
they were using heroin or another substance.44 This can result in a user inadvert-
ently consuming a significantly more potent and more unpredictable substance than 
intended.3,31 In addition to the risks associated with the potency of fentanyl and its 
analogues, fentanyl products sold online and on the black marker pose a threat to 
public health, not least because of variable components and erratic adulteration.3,17 
For example, in a study of fentanyl injecting in Toronto, people who used the drug 
reported that the potency of the substance was unpredictable.47
The use of fentanyls can be also associated with dysphoria, depression, paranoia and 
hallucinations. Adverse effects of fentanyl include constipation, nausea, vomiting, 
itching, cough suppression, nasal burn or nasal drip after insufflation, a bitter taste 
after oral ingestion, anxiety, agitation, sweating, disorientation, orthostatic (or 
postural) hypotension and urinary urgency or retention.41,48,49
The risk of overdose is increased by unsafe methods of preparation and administra-
tion (especially intravenous injection), imprecise measuring by users, drug potency 
and users mostly being unaware of what they are consuming.3 As with other drugs 
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sold on the illicit market, they may not contain what is claimed on the packaging. For 
example, a study from Sweden found that NPS products sold as the fentanyl analogue 
butyrfentanyl (butyrylfentanyl) instead mainly contained the more potent fentanyl.50
Acute adverse effects of fentanyl and its 
analogues
The reported acute harms associated with the use of fentanyls are summarised in 
Table 1.
Table 1. Commonly reported features of fentanyl toxicity
Fentanyl toxicity Fentanyl severe toxicity Differences between heroin and 
fentanyl overdoses
•	 Miosis (pinpoint pupils)
•	 Nausea, vomiting 
•	 Anxiety, agitation 
•	 Euphoria, dysphoria 
•	 Depression 
•	 Paranoia 
•	 Hallucinations
•	 Respiratory and central 
nervous system depression
•	 Decreased consciousness
•	 Apnoea
•	 Can lead to deep coma, 
convulsions and respiratory 
arrest.
•	 Sudden-onset chest wall 
rigidity may be associated 
with increased risk of 
mortality
In comparison with heroin, 
intoxication with fentanyl and 
analogues presents with:
•	 increased risk of overdose
•	 more rapid onset of overdose 
•	 more rapid progression of signs 
and symptoms
As with most other opioids, fentanyl intoxication is linked to miosis (pinpoint pupils). 
However, miosis is not always a reliable clinical sign of toxicity for all opioids, as some 
have miosis absent from their toxicity profile. 
Fentanyl and its derivatives are associated with decreased consciousness and a high 
risk of respiratory depression and overdose.51,52,53 Fentanyl causes dose-dependent 
respiratory depression, which has been reported by one study to be maximal 25 
minutes after a single intravenous dose and to last as long as 2–3 hours.48 Fentanyls 
can also be linked to apnoea, severe bradycardia, asystole, convulsions, respiratory 
arrest, deep coma and death.54
Fentanyl toxicity has been associated with chest wall rigidity, particularly when 
injected.40,41,48,49 There are suggestions that sudden-onset chest wall rigidity is a 
significant factor in deaths from intravenous fentanyl use.55 
Uncommon features of toxicity
Uncommon or rare symptoms described by case reports in the literature include:
•	immediate blue discolouration of the lips, gurgling sounds with breathing, stiffening 
of the body or seizure-like activity, foaming at the mouth, and confusion or strange 
affect before unresponsiveness;56 
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•	lung damage, including alveolar haemorrhage, haemoptysis and acute lung injury, 
with butyrfentanyl;57
•	toxic leukoencephalopathy characterised by cerebellar white matter;58
•	syncope and chest pain mimicking acute coronary syndrome;59 
•	unusual amnestic syndrome associated with combined fentanyl and cocaine use 
that included acute, complete and bilateral hippocampal lesions on magnetic 
resonance imaging.60 
Differences between heroin and fentanyl 
acute toxicity
The high potency of fentanyls, as well as their rapid onset of action, contributes to 
making them in a non-clinical context particularly dangerous in comparison with 
heroin.12,50,61 A report from a drug consumption room in Australia found that, under 
medical surveillance, the risk of overdose when injecting fentanyl was two times 
higher than when injecting heroin, and eight times higher than when injecting other 
prescription opioids.62 
There are differences between fentanyl and heroin overdoses. Fentanyl overdose can 
begin suddenly, rapidly progress to death and manifest atypical physical symptoms. 
In comparison with heroin overdose, where death typically does not occur until at 
least 20–30 minutes after use,63 fentanyl can be associated with potentially lethal 
respiratory depression within 2 minutes.17,30
Fatalities associated with fentanyl often also involve the concurrent use of other 
substances, such as cocaine and heroin.2,64,65 The use of fentanyl (and analogues) at 
the same time as other CNS depressants (e.g. alcohol, benzodiazepine, pregabalin, 
gabapentin) can have serious adverse effects; poly-drug use has been reported to be 
common among fentanyl-related fatalities in Europe21 and elsewhere.34
Injecting is the most commonly reported route of administration of fentanyl in fatal 
overdoses, but deaths linked with other modes of use of fentanyl have also been 
reported. For example, a study looking at fentanyl-related deaths in the US from July 
to December 2016 reported that one in five deaths involving fentanyl or fentanyl 
analogues had evidence of insufflation, smoking or ingestion and no evidence of 
injecting.66 This is an important distinction from heroin, whereby deaths are most 
likely to be associated with intravenous injecting.
Fentanyl-related deaths
The non-medical use of fentanyl has recently been implicated in a significant and 
increasing number of deaths in several countries, including some European countries, 
Australia and Japan.40,67,68,69,70 In Canada and the US, the problem of opioid-related 
overdose death has particularly severe for a number of years.5,71,72,73,74
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There is a debate over the true extent of fentanyl deaths in the US, but the Center 
for Disease Control and Prevention (CDC) reports that the death rate from the use of 
synthetic opioids other than methadone, and which includes drugs such as tramadol 
and fentanyl, increased by 72.2% from 2014 to 2015. According the Center, recent state 
reports have indicated that increases in the numbers of deaths involving synthetic 
opioids have been associated with drug products testing positive for fentanyl, but 
not fentanyl prescribing rates. The suggestion is that the increases in the numbers 
of deaths involving synthetic opioids are being driven by increases in the numbers 
of deaths involving fentanyl, which are likely due to illicitly manufactured fentanyl.75 
Provisional data published on the CDC website suggest an increase from 9,945 deaths 
in 2016 associated with synthetic opioids (excluding methadone) to 20,145 from 
1 January 2017 to 8 June 2017.76 
Deaths related to synthetic opioids, including fentanyls, have been reported in Europe, 
albeit at a significantly lower rate. During 2016, the EMCDDA and Europol launched 
special investigations into acryloylfentanyl and furanylfentanyl, after signals were 
detected through the EU Early Warning System. More than 50 deaths were reported, 
many of which were attributed directly to these substances. In addition, the EMCDDA 
also issued five alerts to its network across Europe related to these and other new 
fentanyls.70,77
In the UK, data from the Office for National Statistics suggest that deaths associated 
with fentanyl and its analogues are increasing, as can be seen in Figure 3. It is possible 
that increased vigilance on the potential implication of fentanyl compounds in opioid 
overdose death will increase detection.
Figure 3. Number of fentanyl-related deaths, where selected substances were mentioned on 
the death certificate, deaths registered in England and Wales, 2012–2016 78
According to the UK National Crime Agency, it is possible that the number of deaths 
attributed to fentanyl will rise further, due to the time lag in toxicology results, and 
because of back testing of toxicological samples originally not tested for fentanyl.79 
It was reported in July 2017 that exposure to carfentanyl had been analytically 
confirmed in 29 deaths in the UK, 28 of which occurred between February and May 
2017.80 However, many of these deaths also involved heroin and it is difficult to assess 
accurately the significance of the presence of fentanyl.
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A study of 25 fatalities in the north of England associated with fentanyl and fentanyl 
derivatives reported that the majority were men, with a history of heroin use, aged 
from 21 to 54 years.81
Poly-drug use 
As with other opioids, the combined use of fentanyl with other CNS and respiratory 
depressants, such as alcohol or benzodiazepines, is linked to increased toxicity. Studies 
have recommended the ongoing need for targeted messages on risks of synthetic 
opioids alone, as well as their use in combination with alcohol and other CNS 
depressants.82
Interactions	with	other	drugs
•	The use of fentanyl in combination with inhibitors of the isoenzymes CYP450 
3A4 and CYP450 3A5 may result in increased plasma concentration of fentanyl 
(and probably new analogues), thus increasing the risk of poisoning, including 
potentially fatal respiratory depression. Inhibitors include ritonavir, clarithromy-
cin, erythromycin, fluconazole, indinavir, itraconazole, ketoconazole, nefazodone, 
saquinavir, verapamil and grapefruit juice.21
•	There is limited evidence that use of fentanyl with serotoninergic agents (prescribed 
medication including SSRIs, SNRIs or MAOIs, or illicit substances, such as MDMA) 
may be associated with serotonin syndrome.83 It is not known if this association is 
also seen with fentanyl derivatives.21
•	Buprenorphine is predicted to increase the risk of opioid withdrawal when given 
with fentanyl.84
Other types of exposure to fentanyls 
The risks associated with fentanyl and its analogues are not limited to its direct 
consumption and some professionals may come into contact with them (e.g. border 
control staff, enforcement officers). Adverse effects may result from handling the drugs 
without the precautions that prevent the substance from being inhaled or absorbed 
through the skin or mucous membranes.3 The current official US government safety 
advice for first responders reinforces the following points:85
•	Fentanyl can be present in a variety of forms (e.g. powder, tablets, capsules, 
solutions and rocks).
•	Inhalation of airborne powder is most likely to lead to harmful effects, but is less 
likely to occur than skin contact.
•	Incidental skin contact is not expected to lead to harmful effects if the contaminated 
skin is promptly washed with water. 
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•	Personal protective equipment (PPE) is effective in protecting people from exposure. 
•	Slow breathing or no breathing, drowsiness or unresponsiveness, and constricted 
or pinpoint pupils are the specific signs consistent with fentanyl intoxication.
•	Naloxone is an effective medication that rapidly reverses the effects of fentanyl.
In the UK, the Home Office Centre for Applied Science and Technology recommends 
that Border Force staff use personal protective equipment (PPE) when handling 
unknown bulk NPS compounds. 
Fentanyl has also been used as a human incapacitation agent, for example in an 
incident in a Moscow theatre in October 2002, where it caused the death of a large 
number of hostages.86,87,88,89
Lack of testing
Analytical methods for detecting fentanyl use are very limited at present and it is 
unlikely that onsite testing is currently available in hospital laboratories. 
Standard immunoassay screening tests in the clinical setting do not detect synthetic 
opioids. More complex methods are required, such as gas chromatography mass 
spectrometry or liquid chromatography mass spectrometry. Testing is complicated 
by the fact that tests for fentanyl may not detect all analogues.
Overdose management
The evidence on the management of acute adverse effects associated with the misuse 
of fentanyls is limited, but emerging.17
There are clear distinctions between the responses to overdose carried out in 
community settings and responses in hospital or other acute medical settings.
In community settings 
As part of a drive to reduce the number of drug-related deaths in the UK, there has 
been a widening of the distribution of naloxone, an antidote to overdoses of opioids, 
including fentanyls. Since 2015, people employed in or otherwise engaged in drug 
treatment services can supply naloxone that has been obtained by their drug service 
to others, as long as it is for the purpose of being available to save life in emergency. 
Although naloxone is a prescription-only medicine, a prescription is not needed for 
the naloxone to be supplied in this way. There is good evidence that pre-provision 
of naloxone to heroin users can be helpful in reversing heroin overdoses. There is 
also evidence for the effectiveness of training family members or peers in how to 
administer the drug.90
Extensive guidance has been issued in the UK on the provision of naloxone for the 
reversal of opioid overdoses in the community.90 The prompt administration of the 
antidote in emergency situations can reverse respiratory depression and can be 
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lifesaving, but giving too much can lead to an acute withdrawal syndrome. To that 
effect, UK Medicines Information (UKMi) recommends that, in community settings, 
the following should take place for the management of opioid overdose:91 
•	An intramuscular dose of 400 µg is given initially, with further 400 µg doses given 
incrementally every 2–3 minutes until an effect is noted or the ambulance arrives.
•	Total available naloxone in a community overdose situation before an ambulance 
arrives is unlikely to exceed 2 mg (five 400 µg doses), which is the amount at which 
the BNF recommends the diagnosis of opiate overdose be reviewed.
Until evidence is available to suggest otherwise, this also applies to the reversal of 
suspected fentanyl overdose.
There is presently no evidence that higher doses of naloxone should be used in 
community settings. In the US and Canada, where morbidity and mortality associated 
with fentanyl misuse is significantly higher than in the UK, a few small-scale inter-
ventions targeted at fentanyl have been developed based on the assumption that 
take-home naloxone kits provided to users of novel synthetic opioids may require 
higher doses of naloxone than those provided to heroin users.92 There are reports of 
some naloxone programmes providing more than the standard two doses of naloxone, 
and others have begun utilising higher-dose devices.17 It is not clear yet whether these 
approaches will prove to be effective. 
There are also some suggestions from North America that naloxone programmes 
should be adapted to take into account the dynamic opioid problem (and fentanyl 
and its analogues in particular), including scale-up to new venues and social networks 
for distribution. There are some suggestions of new standards for post-overdose 
care, the development of supervised drug consumption services and the integration 
of new technologies to detect overdose and deliver naloxone.17 We do not know how 
effective such interventions would be in reducing fentanyl-related deaths.
In hospital settings
It has been argued NPS opioids, including fentanyls, do not require hospital clinical staff 
to change their approach to the management of acute opioid toxicity and overdose.4
•	 It has been suggested that where there is suspicion that fentanyl is implicated, the 
importance of calling ambulance or emergency services promptly and transfer to 
hospital should be emphasised, especially in cases where naloxone is not available 
in the community, or if there is need for prolonged naloxone administration, which 
may be the case of fentanyl overdose. 
•	 It has also been suggested that more advanced resuscitation skills (such as 
chest compressions and automatic defibrillators) may need to be more widely 
incorporated into community emergency response training to tackle fentanyl 
overdose, and is vital if responsiveness to naloxone administration is inadequate 
or delayed.17
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•	It has been suggested that initial care of the opioid-intoxicated patient should 
focus on protecting the airway and maintaining breathing and circulation, as in 
any emergency. External stimulation should be attempted in all patients, and 
an external ventilatory support mask device should be provided for those with 
profound hypoventilation.4
•	Anticipatory titration of naloxone with the goal of restoring ventilatory drive 
remains the mainstay for patients who do not respond in a sustained fashion to the 
above.4 Overdoses can be reversed through the use of naloxone as in the case of 
other opioids, together with appropriate supportive care.93 
•	 It has been proposed that clinical suspicion may be sufficient to carry out empirical 
treatment with naloxone, considering that there are no significant side-effects to 
its use in such circumstances.93 
•	 Potent, faster-acting synthetic opioids, such as fentanyls, make it more difficult 
to balance the need for an effective opioid antidote with the risks of precipitated 
withdrawal.94
An alert issued by the UK Department of Health in April 201795 recommended the 
standard naloxone dosing regime where fentanyl/carfentanyl overdose is suspected 
(for adults and children aged over 12 years) for use in acute hospitals, subject to 
clinical assessment of the individual case:
•	Give an initial dose of 400 µg (0.4 mg) intravenously.
•	If there is no response after 60 seconds, give a further 800 µg (0.8 mg).
•	If there is still no response after another 60 seconds, give another 800 µg (0.8 mg).
•	If there is still no response, give a further 2 mg dose. Large doses (4 mg) may be 
required in a seriously poisoned patient.
•	Aim for reversal of respiratory depression, not full reversal of consciousness.
There are reports of multiple doses of naloxone sometimes being required.56 Because 
the length of time between substance use and potentially life-threatening respiratory 
depression is shorter with fentanyl than with heroin, the reversal of the fentanyl 
overdose may be less likely than with heroin. There have been reports of unsuccessful 
attempts to revive with naloxone despite administration of multiple or escalating 
doses. Despite the standard resuscitation procedures indicating the potential need to 
administer repeat doses of naloxone, the clinical outcome of fentanyl poisoning may 
vary from case to case.96
In comparison with heroin overdose
There are other differences between the management of heroin overdoses and those 
related to fentanyls.
•	In cases of fentanyl overdose, it seems that more rapid administration, and perhaps 
escalation, of additional doses of naloxone is needed in comparison with overdoses 
of heroin or other opioids.
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•	In cases of heroin overdose, some have suggested that patients with heroin-induced 
respiratory depression can be safely discharged from hospital after a one-hour 
observation period.97 Armenian et al. argued that this is not recommended for 
synthetic opioids, including fentanyls, which require larger and repeated doses of 
naloxone and require a longer period of observation because symptoms may recur 
when the naloxone wears off.18 
•	They also recommend that due to the extremely high potency and lack of human 
pharmacokinetic and clinical overdose knowledge of carfentanyl, that all carfentanyl 
cases be monitored for 24 hours in the hospital setting.18
Chronic effects and dependence
Despite limited evidence, it is assumed that fentanyls, including the novel analogues, 
have a high potential for harmful use and a high dependence liability that is similar to, 
or greater than, that with morphine. 
Increasing numbers of people are entering drug treatment for fentanyl-related harmful 
or dependent use. In the US, where there is currently a significantly higher level of 
fentanyl use than in the UK, a study of people entering drug treatment reported 
that fentanyl misuse increased modestly from 2012 to 2016. However, it also showed 
that whereas the misuse of branded fentanyl products remained stable, the misuse 
of ‘unknown’ fentanyls, presumed to be non-pharmaceutical fentanyl, increased 
significantly.98 In Estonia, data from specialised drug treatment centres indicate that 
opioids (mainly non-pharmaceutical fentanyl or 3 methylfentanyl) were the most 
commonly reported primary substances for first-time clients entering treatment in 
2015. In recent years, fentanyl has become the main injected opioid substance in that 
country.99
Fentanyls are associated with tolerance and withdrawal symptoms. Reports from 
users suggest the development of tolerance, withdrawal-like symptoms and 
Differences	between	the	management	of	overdoses	caused	by	heroin	and	
fentanyls
The broad principles of management apply to all opioids, with the following to be 
taken into account where fentanyl is suspected:
•	Where the use of fentanyls is suspected, there is a need to call emergency services 
and transfer to hospital, especially in cases where naloxone is not available in the 
community, or if there is need for prolonged naloxone administration.
•	A more rapid escalation of additional doses of naloxone may be needed in 
comparison with heroin or other opioids. 
•	Overall, higher doses of naloxone may be needed for fentanyl patients than for 
heroin patients.
•	A longer period of observation is advised for fentanyl patients than for heroin 
patients. 
•	 It has been recommended that all cases of overdose with carfentanyl, due to its 
extremely high potency, be monitored for 24 hours in the hospital setting.
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physiological dependence similar to those with other opioids.100,101 Characteristic 
withdrawal symptoms include sweating, anxiety, diarrhoea, bone pain, abdominal 
cramps and shivers or ‘goose flesh’.40,41 
There is little published information on the management of dependence and 
withdrawal for fentanyl misuse or its analogues. Methadone has been used. In Estonia, 
where the most commonly reported primary substances for first-time clients entering 
treatment in 2015 were fentanyls, most clients received opioid substitution therapy 
(OST) and methadone in particular.99 
Other long-term effects
There is some limited evidence that the long-term use of fentanyl has also been 
associated with:
•	hyperalgesia (opioid-induced abnormal pain sensitivity, also called paradoxical 
hyperalgesia);102
•	gastrointestinal disturbance;103
•	immunological dysfunction;103 
•	hormonal disruption;103 
•	muscle rigidity and myoclonus.103
Among older people in particular, long-term use of fentanyl is linked to raised risk of 
fracture and acute myocardial infarction104 and generally increased mortality.105
Public health risks: injecting and other 
high-risk drug-using behaviours
It has been argued that fentanyl and its analogues pose distinct risks for the trans-
mission of blood-borne viruses such as hepatitis C and HIV.47 There is also some evidence 
that use is associated with high-risk behaviours. Users of illicit fentanyl in Toronto, for 
example, reported engaging in practices that exposed them to blood-borne viruses.47 
It has also been associated with bacterial infections and vein damage, with one study 
showing how fentanyl injecting-related harms are exacerbated by the use of lemon 
juice or vinegar, which can cause vein damage when injected.100
There have been suggestions that fentanyl-specific harm-reduction information 
be developed. Commenting on the increase of fentanyl-related deaths in Australia, 
Alan et al. in 2015 stated that ‘An increase in fentanyl-related overdoses and deaths 
suggests that information about how to reduce harms associated with injecting 
fentanyl is lacking’. In their study of the non-medical use of fentanyl patches, users 
reported lack of knowledge of the drug they were using, including exactly what it 
was, how to extract it and how to measure the dose. Peer networks were identified 
as the key source of information in drug-using practices, but information shared was 
poor, even dangerous.100
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Key	points
•	Fentanyls are very potent synthetic opioid receptor agonists. When misused, they 
are associated with a high risk of acute toxicity.
•	There are no rapid urine or serum tests for the detection of non-pharmaceutical 
fentanyls.
•	 In comparison with heroin, fentanyls have a shorter duration of effect, especially 
when injected. 
•	Common features of fentanyl toxicity include: miosis, nausea, vomiting, anxiety, 
agitation, euphoria, dysphoria, depression, paranoia, hallucinations.
•	Fentanyl severe toxicity is characterised by decreased consciousness, apnoea, 
and respiratory and central nervous system depression. It can lead to deep coma, 
convulsions and respiratory arrest. Sudden onset chest wall rigidity may be 
associated with increased risk of mortality.
•	 In comparison with heroin overdoses, overdoses of fentanyl and analogues are 
associated with greater risk, and more rapid onset and progression.
•	The broad principles of management apply to all opioids, with the following to be 
taken into account.
•	Where the use of fentanyls is suspected, there is a need to call emergency services 
and transfer to hospital, especially where naloxone is not available in the community, 
or if there is need for prolonged naloxone administration.
•	Guidance is available in the UK on the administration of naloxone in the community 
and in hospital settings. Overall, the evidence suggests that:
•	A more rapid administration of naloxone is warranted because of the rapid 
onset of fentanyls.
•	A more rapid escalation of additional doses for naloxone may be needed in 
comparison with heroin or other opioids. 
•	Overall, higher doses of naloxone may be needed for fentanyl patients in 
comparison with heroin patients.
•	Fentanyl patients may require a longer period of observation in hospital than 
heroin patients. 
Reporting	adverse	effects	of	NPS	in	the	UK
•	 If you do come across a case of suspected harm from any new psychoactive 
substance (NPS) or other drug, please report it to Report Illicit Drug Reactions 
(RIDR) at https://report-illicit-drug-reaction.phe.gov.uk, a joint initiative between 
Public Health England (PHE) and the Medicines and Healthcare products Regulatory 
Agency (MHRA).
•	For up-to-date guidance on the management of acute toxicity linked to opioids, 
including fentanyl, it is recommended that information be sought from the 
database of the National Poisons Information Service (NPIS), TOXBASE® https://
www.toxbase.org. 
•	The NPIS 24-hour telephone helpline (in the UK 0844 892 0111 and Ireland NPIC 
(01) 809 2566) is available for discussion of more complex cases. When appropriate, 
senior medical staff can discuss their cases directly with an NPIS consultant clinical 
toxicologist. Non-UK readers should consult their local or national guidelines and 
poison information services. 
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Section 3. Other novel synthetic 
opioids
In addition to fentanyl and its analogues, in the past five years more than a dozen 
additional synthetic opioids have entered the illicit opioid market. Some of these novel 
synthetic opioids have been rediscovered by traffickers from research done between 
the 1960s and 1990s, when they were described in the scientific literature but never 
developed into pharmaceutical products. 
Newly marketed synthetic opioids have appeared with structures distinct from 
those used in medical practice. Examples include, but are not limited to, AH-7921 
(a benzamide), U-47700 (a compound closely related to AH-7921) and MT-45 (a 
piperazine):
•	AH-7921 is 3,4-dichloro-N-(1-(dimethylamino)cyclohexylmethyl)benzamide;
•	U-47700 is trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenz amide;
•	MT-45 is 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine.
These were all first synthesised in the 1970s.8 The pharmacology, availability and 
modes of use of these three substances are outlined in Table 2. The effects desired by 
users are listed in Table 3.
Unwanted and adverse effects of intoxication
AH-7921, U-47700 and MT-45 have similar profiles of unwanted and adverse effects. 
Further details are given in Table 4.115
Signs of toxicity115
•	Miosis (pinpoint pupils), with the exception of MT-45, which has only a small miotic 
effect
•	Nausea, vomiting 
•	Anxiety, agitation 
•	Euphoria, dysphoria 
•	Depression 
•	Paranoia 
•	Hallucinations
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Table 2. Pharmacological and other properties of three novel synthetic opioids
AH-7921 U-47700 MT-45
Pharmacology
AH-7921 is an opioid analgesic 
that was patented by Allen and 
Hanburys Ltd in 1976 but that has 
never been used as or in a pharma-
ceutical or medicinal product. 
Thought to be a morphine-like 
analgesic acting mainly as a 
µ-opioid receptor agonist. Human 
data are mostly not available, 
but animal studies have shown 
that AH-7921 is approximately as 
potent as morphine with regard 
to respiratory depression, anti-
nociception, sedation and miosis 
(decrease in pupil diameter), 
Straub tail, decrease in body 
temperature and inhibition of gut 
propulsion.106,107,108 
U-47700 is an opioid analgesic 
and is structurally related to 
AH-7921. 
Although U-47700 exhibits 
some k-opioid receptor 
agonism, it has far more 
activity at the µ-opioid 
receptors.42
It is a selective µ-opioid 
receptor agonist, and in 
animal models has been 
demonstrated to have 
~7.5 times the potency of 
morphine.109,110
According to user reports, 
U-47700 acts longer than 
AH-7921.20
MT-45, also known as 
IC-6, was developed in the 
1970s as an alternative to 
morphine for analgesia. It 
is an N,N-di-substituted 
4-(1,2-diphenylethyl) 
piperazine chemically 
unrelated to other opioid 
agonists. 
The pharmacology of MT-45 
is complex and involves 
opioid and non-opioid 
receptors that have not 
been fully characterised; 
however, it has been 
demonstrated in animal 
studies to have approxi-
mately the same potency as 
morphine.111
It appears that MT-45 has a 
slow onset of action, greater 
than 1–2 hours when taken 
orally, which may increase 
the risk of toxic overdose 
from redosing before peak 
effect is reached.112
Availability and modes of use
AH-7921 has been available 
in Europe since mid-2012 via 
websites selling ‘research 
chemicals’.a
AH-7921 is sold as a free base and 
as a hydrochloride salt in a white/
off-white powder form,108 but 
has also been detected in Japan 
as a co-ingredient in synthetic 
cannabinoid and cathinones.113
AH-7921 is usually consumed 
orally but can also be used by 
inhalation/vaporising, nasal 
insufflation, sublingually, 
intravenous injection or rectal 
administration and is sold as a 
powder, tablet, or capsule. 
In the recreational drug 
market, U-47700 is sometimes 
referred to as ‘pink’, because it 
can be slightly pink in colour. 
The drug is also known as 
‘U4’.1 
It is taken orally, nasally, 
rectally, by smoking, 
intravenous injection, or 
by combinations of these 
routes.20
MT-45 is typically sold 
on the internet or illicit 
market as a dihydrochloride 
salt. Typical routes of 
administration include oral, 
insufflation, intravenous and 
intramuscular. Rectal use 
has also been reported.49 
It has been found mixed 
with other drugs, including 
synthetic cannabinoids and 
synthetic cathinones.114 
a It is often sold or discussed on user websites and public media under the alternative name ‘doxylam’. 
This name could be easily confused with that of ‘doxylamin’ (an antihistamine drug with sedative–
hypnotic properties that is present in several over-the-counter medicines); the unintentional use of 
AH-7921/doxylam bought on the internet for the treatment of allergy or as a hypnotic might have 
serious health consequences.
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Table 3. Desired effects of three novel synthetic opioids
AH-7921 U-47700 MT-45
Much of what we know about its 
effects comes from reports of 
people who have used it. Based 
on this, the effects of AH-7921 
appear to resemble those of 
classic opioids.
AH-7921 produces relaxation, 
euphoria, a physical anaesthetic 
effect, mental relaxation and 
pleasant mood lift.115 
An interesting finding reported 
by one study was that the users 
of AH-7921 (as well as of MT-45) 
report experiences of increased 
energy.116 
There are also reports of its use as 
self-medication to relieve pain or 
to alleviate withdrawal symptoms 
due to cessation of the use of 
other opioids.116 
Based on animal models, it 
is expected that U-47700 
produces effects similar to 
those of other potent opioid 
agonists, including analgesia, 
sedation, euphoria.117 
It has been suggested that 
U-47700 induces significant 
euphoria, which is short-lived 
and causes an urge to keep 
‘redosing’.118
Effects similar to other 
opioids.49
Signs of severe toxicity
•	Severe opioid toxicity produces depression of the respiratory and central nervous 
systems. If untreated the depression of the level of consciousness can lead to deep 
coma, convulsions and respiratory arrest.
Management of acute intoxication and 
overdose
AH-7921, U-47700 and MT-45 require similar management of acute intoxication and 
overdose. These synthetic opioids are currently not tested as a routine part of most 
forensic drug screening. However, it has been argued that the clinical approach in 
managing opioid toxicity and overdose should not change and should include the 
management of airways and the administration of naloxone to reverse the overdose.121
As NPS opioids have various potencies, receptor affinities and street concentra-
tions, it has been argued that it is possible only to speculate about the doses of 
naloxone required for reversal and this should be determined on a case-by-case and 
drug-by-drug basis.4
It has been suggested that emergency responders may have difficulty in identifying 
MT-45 overdose because the drug produces a small miotic effect (restriction of 
pupils).121
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Table 4. Unwanted and adverse effects of intoxication of three novel synthetic 
opioids
AH-7921 U-47700 MT45
A study found that morphine has a twofold 
greater safety margin than AH-7921, which 
suggests readier appearance of toxic 
effects after AH-7921 use.119
The side-effects range from milder 
symptoms (e.g. stomach upsets, light 
headache) to more severe conditions (e.g. 
anxiety and panic).116 
Other reported adverse effects include 
abdominal pain, constipation, reduced 
mobility, light-headedness, headache, 
urinary retention, visual impairment, pain 
in the mouth.
Unwanted adverse effects also include 
vertigo induced by movement.115 
Users also reported itching as one of the 
side-effects of AH-7921 use, as well as 
other forms of skin irritation. There are 
also reports of numbing of different parts 
of the body.116 
Temperature change, tremors, numbness, 
blister, seizures, hypertension and 
tachycardia have also been reported.120 
Based on animal 
models, is expected 
that U-47700 
produces effects 
similar to those of 
other potent opioid 
agonists including 
constipation, itching 
and respiratory 
depression.117
It has been suggested 
that U-47700 induces 
significant euphoria, 
which is short-lived 
and causes an urge to 
keep ‘redosing’.118
MT-45 has only a	small 
miotic effect (restriction of 
pupils or pinned pupils),121 in 
contrast to other commonly 
used opioid drugs.
Although MT-45 is 
structurally unrelated to 
morphine, it has analgesic 
and CNS depressant 
properties similar to those 
of morphine, including 
respiratory depression.122 
Some animal studies suggest 
a higher toxicity than 
morphine.122
Drug users also report 
some dissociative-like 
symptoms.111 
Other reported unwanted 
effects include nausea, 
itching, bilateral hearing 
loss and possible withdrawal 
symptoms. A unique feature 
of MT-45 toxicity is its 
association with ototoxicity 
– that is, it is linked with 
hearing loss, with a reported 
case of bilateral hearing loss 
lasting for two weeks.49,112
Deaths
AH-7921 has been associated with fatal 
overdoses, including a small number of 
deaths in the UK.108,123,124,125,126,127 
Deaths associated with AH-7921 seem to 
occur both at low and high concentrations, 
possibly a result of different levels of 
tolerance to the drug.128 
As with other overdose deaths, poly-drug 
use has been involved in many AH-7921 
deaths,106,115 but AH-7921 use alone has 
also been reported.128 
Deaths reported.117,118 Deaths reported in Europe 
and elsewhere.49,117,129,130,131,132
Chronic effects and dependence
Despite limited evidence, it is assumed that AH-7921 and U-47700 have a high 
addictive potential similar to or greater than that of morphine.49,133 Reports from users 
suggest the development of tolerance and of withdrawal-like symptoms with MT-45, 
AH-7921 and U-47700 is similar to that with other opioids.
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Section 4. Concluding remarks and 
key points
At the time of writing, synthetic opioids, including fentanyls, used for non-medical 
purposes in the UK can be described as ‘low use but high risk/harm’ substances. 
Vigilance is required, as well as improved confidence and competence in the identifi-
cation, assessment and management of their harms in clinical practice.
The literature suggests that the management of the acute and chronic harms 
associated with the novel synthetic opioids should be based on the same approach 
used by clinicians in the management of other acute opioid toxicity and overdose, 
including airway management and naloxone for the reversal of overdose. The literature 
also suggests the need for a greater understanding of, and a better response to, 
the factors specific to these novel synthetic drugs and which make their harms and 
management different from those for heroin, for example. 
Key	points
•	Synthetic opioids, including novel opioids, are increasingly available on the illicit 
market and often mis-sold as other drugs.
•	The adverse effects of these substances are similar to those of other opioid drugs 
and include the risk of acute toxicity, overdose and dependence.
•	Symptoms of overdose from these synthetic opioids can, however, differ from 
those of heroin. Fentanyls, for example, appear to cause more rapid respiratory 
depression.
•	As with other opioid drugs, poly-substance misuse (particularly with other 
sedatives) increases the risk of adverse effects.
•	Clinical management of suspected overdoses with synthetic opioids, including 
fentanyl and analogues, should follow protocols for opioid overdose (airway, 
breathing and circulation: ABC), with a low threshold for administration of naloxone.
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